teala stock: Tela Bio, Inc. (TELA) overview
Tela Bio, Inc. (Ticker: TELA)
As of Jan 27, 2026, according to Tela Bio's public filings and press releases, this article summarizes Tela Bio's business, products and market context. If you are researching teala stock, this guide explains Tela Bio’s product focus, operations, governance, key risks and where to verify the most recent financial and market data.
Note: this article is informational and not investment advice. For precise, up‑to‑date financial figures and market data on teala stock, consult Tela Bio’s latest SEC filings, investor presentations and market quote services.
Company overview
Tela Bio, Inc. is a commercial‑stage medical technology company focused on reinforced tissue matrix products used in soft‑tissue reconstruction and hernia repair. The company’s core product family is marketed under the OviTex brand name. Headquartered in Malvern, Pennsylvania, Tela Bio was founded in 2012 and develops biologically derived matrices combined with synthetic or biologic reinforcement fibers to support tissue repair and regeneration.
Tela Bio’s market focus is primarily surgical specialties that include general surgery (hernia and abdominal wall reconstruction) and plastic & reconstructive surgery. Its products are intended for use by hospitals and ambulatory surgery centers and distributed through a commercial sales organization in the United States and channel partners in selected international markets.
Throughout this article the keyword teala stock is used to help you find this content when researching Tela Bio’s equity and public market profile.
History and corporate milestones
Tela Bio was founded in 2012 with the technical objective of combining biologic matrices with reinforcement to better support soft‑tissue repair. Key milestones in the company’s history include product development and regulatory work to bring the OviTex family to market, commercial launch and expansion of sales coverage in the U.S., and equity capital raises to fund commercialization and development.
- Early years (2012–2016): research and product development, preclinical studies and preparation for clinical evaluation.
- Product commercialization: progressive rollouts of the OviTex family into surgical markets, including specific product variants designed for abdominal wall reconstruction and for plastic & reconstructive surgery.
- Public reporting and financings: the company’s transition to public reporting and periodic equity and debt financings intended to support commercial expansion.
Investors tracking teala stock typically review press releases and SEC filings to follow these milestones, including product clearances, reimbursement developments and material financings.
Products and technology
Tela Bio’s commercial value proposition centers on the OviTex reinforced tissue matrix platform, which combines a biologic extracellular matrix derived from ovine (sheep) tissue with a reinforcing fiber or grid to provide mechanical strength while encouraging tissue integration and remodeling.
OviTex Reinforced Tissue Matrix
The OviTex family is positioned as a reinforced tissue matrix for soft‑tissue reconstruction and hernia repair. Intended clinical applications include ventral and incisional hernias, abdominal wall reconstruction and other soft‑tissue repair procedures where reinforcement and host tissue remodeling are desirable. The material basis is an ovine‑derived extracellular matrix scaffold combined with a reinforcing component (fibers or mesh) to provide mechanical integrity during early healing while permitting gradual host tissue integration.
Clinically, the OviTex design aims to reduce the foreign‑body response associated with permanent synthetic meshes, while providing greater strength than many biologic matrices. Commercially, the company positions OviTex as a differentiated option for surgeons seeking a balance between strength and biologic remodeling.
OviTex PRS and minimally invasive offerings
Tela Bio has extended the OviTex platform into variants designed for plastic & reconstructive surgery (PRS) and for minimally invasive approaches, including laparoscopic and robotic procedures. The PRS variants emphasize applications such as abdominal wall reconstruction in complex repair and reconstructive situations where contour and tissue integration are important.
The company has introduced larger‑sized configurations and packaging intended to better serve minimally invasive workflows and broader surgeon preferences. These product extensions aim to increase procedural adoption by covering a wider range of clinical scenarios and operative techniques.
Business model and operations
Tela Bio’s commercial approach in the U.S. has emphasized a direct sales force targeting hospitals, health systems and surgeon groups. Outside the U.S., distribution partners and regional agreements are used to access selected markets.
Primary revenue streams come from product sales of the OviTex family. Typical customers are hospital purchasing departments, surgical departments and individual surgeons specializing in general, trauma and plastic surgery. The company’s operating model includes investing in clinical support, surgeon education, reimbursement assistance and a sales infrastructure to drive adoption.
Manufacturing and sterile supply are important operational elements for a surgical‑implant company. Tela Bio has relied on third‑party manufacturing and contract manufacturing organizations for certain processing and sterile packaging operations while maintaining quality systems and regulatory oversight. Investors examining teala stock commonly evaluate the company’s supply‑chain disclosures to understand capacity, risks and costs associated with manufacturing.
Financial performance
Tela Bio is a growth‑oriented, commercial‑stage company that historically has invested heavily in commercialization and product development. The company has reported top‑line growth periods alongside operating losses as it scales sales and supports R&D and clinical programs. When researching teala stock, it is important to view the most recent audited annual report (Form 10‑K) and interim reports (Form 10‑Q) for exact revenue, net loss and cash position figures.
As of Jan 27, 2026, according to Tela Bio’s public filings and investor presentations, Tela Bio has shown revenue growth tied to expanded clinical adoption of OviTex products while continuing to record operating losses due to commercial and R&D investment.
Key financial metrics
Investors reviewing teala stock usually look for: annual and quarterly revenue, net income (loss) trends, operating cash flow and EBITDA or adjusted operating metrics, cash and cash equivalents, and debt or credit facilities. These figures are reported in the company’s periodic SEC filings and are the authoritative sources for quantifiable metrics.
- Revenue trend: Tela Bio has reported revenue consistent with a commercial‑stage device company expanding sales coverage. Verify the exact annual revenue and year‑over‑year change in the latest 10‑K.
- Net income (loss) trend: the company has historically been unprofitable while investing in commercialization; net losses and operating cash burn are typical.
- Cash position and indebtedness: Tela Bio’s balance sheet items such as cash on hand and outstanding debt or credit facility usage are disclosed in each quarter’s 10‑Q; these items materially affect financing and dilution risk for teala stock.
For precise numeric values—recent annual revenue, net loss, EBITDA or operating loss figures, cash balances and outstanding debt—consult the latest Form 10‑K and Form 10‑Q available on the SEC’s EDGAR system or Tela Bio’s investor relations materials.
Recent quarters & guidance
Quarterly trends for teala stock depend on product sales growth, gross margins, operating expenses and non‑operating items such as interest and one‑time charges. Tela Bio historically has issued quarterly results with management commentary on revenue drivers, clinical adoption and cash runway. The company may also provide guidance or commentary about expected revenue trends or financing plans in earnings releases or investor presentations.
Material financings—such as follow‑on equity offerings, convertible note issuances or credit facilities—are commonly disclosed in press releases, 8‑K filings and the notes to financial statements. Investors tracking teala stock should carefully read those disclosures to assess dilution risk and capital sufficiency.
Stock and market information
Tela Bio trades on the NASDAQ exchange under the ticker symbol TELA. The company is often considered a small‑cap or micro‑cap by market capitalization standards, and teala stock typically exhibits higher volatility and trading volume characteristics common to smaller medical‑device equities.
Price history and trading data
Price movements for teala stock have historically reflected company newsflow—earnings results, product announcements, clinical data releases and financing events often drive noticeable intraday and multi‑day movements. Volume characteristics can vary widely; smaller‑cap securities sometimes see thin trading days and larger spreads. For current 52‑week range, recent share‑price movement and volume statistics, consult up‑to‑date market data providers or your brokerage platform.
Market capitalization and shares outstanding
Market cap and shares outstanding change with market price and equity events. When analyzing teala stock, note the market cap at a particular timestamp and the latest reported shares outstanding in the company’s filings. These are the authoritative sources for market capitalization calculations.
Analyst coverage & price targets
Analyst coverage of teala stock is typically limited compared with larger medical‑device firms. Where coverage exists, analysts may publish varying ratings and price targets based on their assessment of the OviTex commercial traction, gross margins, clinical evidence and capital structure. Investors should compare any published analyst views with the company’s own disclosures and independent data.
Ownership and major shareholders
Ownership of teala stock includes a mix of institutional investors, insider holdings (executives and board members) and retail investors. Institutional ownership and notable holders are typically disclosed in proxy statements, Form 10‑K/10‑Q exhibits and in financial data services. Insiders such as officers and directors report equity positions in SEC forms (Forms 3, 4 and 5), which are useful for seeing recent insider purchases or sales.
When researching teala stock, check the most recent beneficial ownership tables and Form 4 filings for up‑to‑date insider activity and institutional holdings percentages.
Management and corporate governance
Tela Bio’s management team and board composition are central to assessing execution capability. Key roles to note include the Chief Executive Officer, Chief Medical Officer, Chief Financial Officer, and the Board Chair or Lead Independent Director. Recent executive appointments, board changes or governance disclosures are typically described in press releases and proxy statements.
Investors watching teala stock should review executive biographies to understand experience in medical devices, surgical markets, commercialization and regulatory affairs. Governance disclosures—such as committee composition, independence determinations and compensation policies—are found in the annual proxy statement.
Clinical evidence, regulatory status and R&D
Clinical evidence and regulatory clearances are core to Tela Bio’s commercial traction. The OviTex family is marketed for soft‑tissue reconstruction and hernia repair; regulatory status in the U.S. (e.g., 510(k) or other device clearance mechanisms) and comparable authorizations in other jurisdictions determine where and how products can be sold.
Tela Bio supports commercialization with clinical studies, investigator‑initiated research and real‑world evidence to demonstrate outcomes such as recurrence rates, complication rates and patient recovery metrics. Ongoing research programs and published clinical data are important for surgeon adoption and payer reimbursement.
When evaluating teala stock, review peer‑reviewed publications, clinical trial registries and the company’s clinical slide decks to assess the depth and quality of evidence supporting OviTex products.
Recent news and developments (selected)
- Product launches and product extensions related to the OviTex family that broaden the range of sizes and configurations for different surgical procedures.
- Quarterly earnings releases reporting revenue trends and management commentary on commercial progress and cash runway.
- Financing events such as equity offerings, credit facility announcements or debt financings which are material to teala stock because of potential dilution and capital availability.
- Regulatory or reimbursement updates that affect market access and adoption of OviTex products.
- Executive appointments or board changes announced in company press releases or SEC filings.
As of Jan 27, 2026, according to Tela Bio’s public releases and SEC filings, the company has continued to focus on commercial expansion and clinical evidence generation; for the exact text and dates of these announcements, consult Tela Bio’s investor relations materials and recent 8‑K filings.
Competitors and market positioning
Tela Bio operates in the broader surgical biologics and mesh market, where competitors include firms offering surgical meshes, biologic matrices and other soft‑tissue repair products. Competing product categories include permanent synthetic mesh, resorbable synthetic scaffolds and other biologic matrices sourced from porcine, bovine or human dermis.
Tela Bio’s market positioning emphasizes a reinforced biologic matrix approach intended to combine biologic remodeling with reinforcement. Competitive advantages and challenges depend on clinical outcomes, cost, surgeon preference, and payer coverage. When assessing teala stock, compare OviTex adoption metrics and clinical outcome data against alternative products and incumbent manufacturers.
Risks and investment considerations
Key risks relevant to teala stock include:
- Small/micro‑cap company risks: limited liquidity, higher volatility and greater susceptibility to market sentiment.
- Historical unprofitability: like many early commercial medical‑device companies, Tela Bio has reported operating losses while investing in sales and R&D.
- Clinical and regulatory risk: the need for robust clinical evidence and regulatory clearances to support broader adoption.
- Financing and dilution risk: dependence on capital markets or credit facilities; equity raises can dilute existing shareholders.
- Market adoption and competitive risk: surgeon preference, cost considerations and competing technologies can limit market penetration.
These risks are typically discussed in the company’s risk factor sections of the Form 10‑K and in quarterly filings; they are material for anyone evaluating teala stock.
Regulatory, legal and safety matters
For a surgical implant company, relevant regulatory and legal disclosures include product safety reviews, recalls, post‑market surveillance findings, and material litigation. Tela Bio’s SEC filings and public releases disclose material legal proceedings, regulatory interactions and any product safety communications.
If material matters exist—such as product recalls or major litigation—those items are announced in press releases and described in the company’s periodic reports. Investors in teala stock should monitor the company’s 8‑K filings and FDA or other regulatory communications for the most current information.
See also
- Surgical mesh market and trends
- Hernia repair devices and techniques
- Biologic matrices and soft‑tissue reinforcement
- Reading SEC filings: Form 10‑K, Form 10‑Q, Form 8‑K and proxy statements
References and further reading
This article recommends primary sources for accurate, verifiable information on teala stock and Tela Bio: the company’s SEC filings (Form 10‑K, Form 10‑Q, Form 8‑K), investor presentations, peer‑reviewed clinical publications on OviTex, and corporate press releases. For market data, consult up‑to‑date market quote pages and your brokerage.
As of Jan 27, 2026, according to Tela Bio’s public filings and investor materials, the descriptions above reflect the company’s stated business, products and strategic focus. For numeric financial figures, market capitalization and exact share counts, review the company’s most recent Form 10‑Q or Form 10‑K and the associated footnotes.
External links
For up‑to‑date resources on teala stock and Tela Bio, consult the following official sources (search the organization or form name in your web browser or brokerage platform):
- Tela Bio official website (investor relations and corporate pages)
- Tela Bio SEC filings (Form 10‑K, Form 10‑Q, Form 8‑K) on the EDGAR platform
- Market quote pages for NASDAQ: TELA on your brokerage or financial data service
How to verify current data on teala stock
- Visit Tela Bio’s investor relations page to download the latest earnings releases and investor presentations.
- Search the SEC EDGAR database for the company’s most recent Form 10‑K (annual report) and Form 10‑Q (quarterly reports) for audited and interim financial statements.
- Check recent Form 8‑K filings for material corporate events (product clearances, financings, executive changes and litigation disclosures).
- Use your brokerage or market‑data provider to view live quotes, 52‑week ranges and volume statistics for NASDAQ: TELA.
Next steps and call to action
If you’re tracking teala stock, begin with Tela Bio’s most recent Form 10‑Q and the latest investor presentation. For active trading, use a regulated brokerage that provides NASDAQ quotes; if you’re exploring broader research, review peer‑reviewed clinical articles on OviTex outcomes and reimbursement guidance.
Explore additional tools and market data available on Bitget for trading and portfolio tracking. For educational materials on equity research and how to read SEC filings, Tela Bio’s investor relations materials and authoritative investor‑education sites can help you interpret reported figures.
Reminder: this article is informational and not investment advice. Always validate current numbers and disclosures directly from Tela Bio’s filings and consult a licensed financial professional before making investment decisions regarding teala stock.
